Date | Time | Source | Headline | Symbol | Company |
05/07/2024 | 8:55AM | GlobeNewswire Inc. | IPSEN SA. - Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée Générale Mixte du 28 mai 2024 | EU:IPN | Ipsen SA |
05/07/2024 | 8:55AM | GlobeNewswire Inc. | Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting | EU:IPN | Ipsen SA |
05/06/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social | EU:IPN | Ipsen SA |
05/06/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital | EU:IPN | Ipsen SA |
05/02/2024 | 1:30AM | GlobeNewswire Inc. | Ipsen appoints Keira Driansky as EVP, President of North America | EU:IPN | Ipsen SA |
05/02/2024 | 1:30AM | GlobeNewswire Inc. | Ipsen appoints Keira Driansky as EVP, President of North America | EU:IPN | Ipsen SA |
05/02/2024 | 1:30AM | GlobeNewswire Inc. | Ipsen nomme Keira Driansky, en qualité de Vice-Présidente Exécutive, et Présidente Amérique du Nord | EU:IPN | Ipsen SA |
04/24/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance | EU:IPN | Ipsen SA |
04/24/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance | EU:IPN | Ipsen SA |
04/24/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 | EU:IPN | Ipsen SA |
04/22/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | EU:IPN | Ipsen SA |
04/22/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | EU:IPN | Ipsen SA |
04/22/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares | EU:IPN | Ipsen SA |
04/17/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen publishes its 2023 Universal Registration Document | EU:IPN | Ipsen SA |
04/17/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen publie son Document d’enregistrement universel 2023 | EU:IPN | Ipsen SA |
04/08/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social | EU:IPN | Ipsen SA |
04/08/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital | EU:IPN | Ipsen SA |
04/02/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen et Sutro Biopharma annoncent la signature d'un accord exclusif de licence mondiale pour un conjugué anticorps-petite molecule ciblant les tumeurs solides | EU:IPN | Ipsen SA |
04/02/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors | EU:IPN | Ipsen SA |
04/02/2024 | 1:00AM | GlobeNewswire Inc. | Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors | EU:IPN | Ipsen SA |
03/07/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital | EU:IPN | Ipsen SA |
03/07/2024 | 12:00PM | GlobeNewswire Inc. | Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social | EU:IPN | Ipsen SA |
02/15/2024 | 4:00AM | GlobeNewswire Inc. | Ipsen S.A. publie ses comptes consolidés 2023 | EU:IPN | Ipsen SA |
02/15/2024 | 4:00AM | GlobeNewswire Inc. | Ipsen S.A. publishes its 2023 Consolidated Financial Statements | EU:IPN | Ipsen SA |
02/13/2024 | 4:08PM | GlobeNewswire Inc. | Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique | EU:IPN | Ipsen SA |
02/13/2024 | 4:08PM | GlobeNewswire Inc. | Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA | EU:IPN | Ipsen SA |
02/13/2024 | 4:08PM | GlobeNewswire Inc. | Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA | EU:IPN | Ipsen SA |
02/08/2024 | 12:58AM | GlobeNewswire Inc. | Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 | EU:IPN | Ipsen SA |
02/08/2024 | 12:58AM | GlobeNewswire Inc. | Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024. | EU:IPN | Ipsen SA |
02/08/2024 | 12:58AM | GlobeNewswire Inc. | Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 | EU:IPN | Ipsen SA |